A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)

NCT00864227 Phase 2 COMPLETED Results posted

A bone marrow transplant, which is a type of stem cell transplant, is a treatment option for people with leukemia or lymphoma. Recently, stem cell transplants using umbilical cord blood have become a treatment option for people with these types of cancers. This study will evaluate the effectiveness of a stem cell transplant using umbilical cord blood, along with lower doses of chemotherapy, to treat people with leukemia or lymphoma.

Details

Lead sponsor	Medical College of Wisconsin
Phase	Phase 2
Status	COMPLETED
Enrolment	54
Start date	2008-12
Completion	2013-11

Conditions

• Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
• Leukemia, Myeloid, Acute
• Burkitt Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Follicular
• Lymphoma, Large B-Cell, Diffuse

Interventions

• Hematopoietic Umbilical Cord Blood Stem Cell Transplantation
• GVHD prophylaxis

Primary outcomes

• Overall Survival at 180 Days From the Time of Transplant — Measured at Month 6 and Year 1

Countries

United States